Medications for Opioid Use Disorder in Medicare in 2023: Annual Review

The opioid crisis remains a public health emergency. In 2023, an estimated 81,842 opioid-related overdose deaths occurred in the United States. Ensuring both that patients who would benefit from treatment for opioid use disorder have access to this treatment and that people have opioid overdose-reversal drugs on hand are key to addressing this crisis. This data brief, Medications for Opioid Use Disorder in Medicare in 2023: Annual Review, builds on our series of annual reports on opioid utilization in Medicare Part D and the treatment of opioid use disorder among people enrolled in Medicare. It provides 2023 data on the number of enrollees who received medications to treat opioid use disorder, the number of enrollees who experienced an opioid overdose, and the number of enrollees who received opioid overdose reversal drugs.

Announced or Revised	Agency	Title	Component	Report Number(s)	Expected Issue Date (FY)
November 2024	Centers for Medicare and Medicaid Services	Medications for Opioid Use Disorder in Medicare in 2023: Annual Review	Office of Evaluation and Inspections	OEI-02-24-00430	2025